The push for clinical trial transparency may be delayed. Pharmalot reports that the European Medicines Agency is wading through more than 1,000 comments supporting the initiative and vociferous attacks from the industry and its backers who claim the initiative will threaten patient safety and corporate intellectual property. Threats to pack up and take jobs elsewhere have also accompanied industry concerns.
The EMA planned on having data out in the open by January 2104. It will decide in December if this date is still possible.
